» Articles » PMID: 22850566

The Rectal Cancer MicroRNAome--microRNA Expression in Rectal Cancer and Matched Normal Mucosa

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2012 Aug 2
PMID 22850566
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: miRNAs play a prominent role in a variety of physiologic and pathologic biologic processes, including cancer. For rectal cancers, only limited data are available on miRNA expression profiles, whereas the underlying genomic and transcriptomic aberrations have been firmly established. We therefore, aimed to comprehensively map the miRNA expression patterns of this disease.

Experimental Design: Tumor biopsies and corresponding matched mucosa samples were prospectively collected from 57 patients with locally advanced rectal cancers. Total RNA was extracted, and tumor and mucosa miRNA expression profiles were subsequently established for all patients. The expression of selected miRNAs was validated using semi-quantitative real-time PCR.

Results: Forty-nine miRNAs were significantly differentially expressed (log(2)-fold difference >0.5 and P < 0.001) between rectal cancer and normal rectal mucosa. The predicted targets for these miRNAs were enriched for the following pathways: Wnt, TGF-beta, mTOR, insulin, mitogen-activated protein kinase, and ErbB signaling. Thirteen of these 49 miRNAs seem to be rectal cancer-specific, and have not been previously reported for colon cancers: miR-492, miR-542-5p, miR-584, miR-483-5p, miR-144, miR-2110, miR-652, miR-375, miR-147b, miR-148a, miR-190, miR-26a/b, and miR-338-3p. Of clinical impact, miR-135b expression correlated significantly with disease-free and cancer-specific survival in an independent multicenter cohort of 116 patients.

Conclusion: This comprehensive analysis of the rectal cancer miRNAome uncovered novel miRNAs and pathways associated with rectal cancer. This information contributes to a detailed view of this disease. Moreover, the identification and validation of miR-135b may help to identify novel molecular targets and pathways for therapeutic exploitation.

Citing Articles

Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer.

Gattuso G, Longo F, Spoto G, Ricci D, Lavoro A, Candido S Int J Mol Sci. 2025; 26(3).

PMID: 39940987 PMC: 11818852. DOI: 10.3390/ijms26031219.


Comprehensive Analysis of a Platelet- and Coagulation-Related Prognostic Gene Signature Identifies CYP19A1 as a Key Tumorigenic Driver of Colorectal Cancer.

Su G, Wang M, Qian J, Wang Y, Zhu Y, Wang N Biomedicines. 2024; 12(10).

PMID: 39457539 PMC: 11505370. DOI: 10.3390/biomedicines12102225.


Oncogenic microRNA-1290 and Gene as Potential Biomarker for Colorectal Carcinoma.

Naseem R, Shahid S, Shahid W, Abbas G Technol Cancer Res Treat. 2024; 23:15330338241286283.

PMID: 39327992 PMC: 11439174. DOI: 10.1177/15330338241286283.


Insight into the Role of the miR-584 Family in Human Cancers.

Braile M, Luciano N, Carlomagno D, Salvatore G, Orlandella F Int J Mol Sci. 2024; 25(13).

PMID: 39000555 PMC: 11242779. DOI: 10.3390/ijms25137448.


Restricting Colorectal Cancer Cell Metabolism with Metformin: An Integrated Transcriptomics Study.

Orang A, Marri S, McKinnon R, Petersen J, Michael M Cancers (Basel). 2024; 16(11).

PMID: 38893174 PMC: 11171104. DOI: 10.3390/cancers16112055.


References
1.
Ritchie W, Flamant S, Rasko J . Predicting microRNA targets and functions: traps for the unwary. Nat Methods. 2009; 6(6):397-8. DOI: 10.1038/nmeth0609-397. View

2.
Findeiss S, Langenberger D, Stadler P, Hoffmann S . Traces of post-transcriptional RNA modifications in deep sequencing data. Biol Chem. 2011; 392(4):305-13. DOI: 10.1515/BC.2011.043. View

3.
Nagel R, le Sage C, Diosdado B, van der Waal M, Vrielink J, Bolijn A . Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008; 68(14):5795-802. DOI: 10.1158/0008-5472.CAN-08-0951. View

4.
Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J . Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer. 2010; 129(7):1624-34. DOI: 10.1002/ijc.25818. View

5.
Lu J, He M, Wang L, Chen Y, Liu X, Dong Q . MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011; 71(1):225-33. DOI: 10.1158/0008-5472.CAN-10-1850. View